Caplin Point Laboratories Limited (IN:CAPLIPOINT)
:CAPLIPOINT
Want to see IN:CAPLIPOINT full AI Analyst Report?
CAPLIPOINT Stock Chart & Stats
₹1845.95
-₹76.70(-2.97%)
At close: 4:00 PM EST
₹1845.95
-₹76.70(-2.97%)
Day’s Range― - ―
52-Week Range₹1,502.45 - ₹2,396.95
Previous CloseN/A
Volume128.91K
Average Volume (3M)3.75K
Market Cap
₹131.17B
Enterprise Value₹124.93B
Total Cash (Recent Filing)₹10.17B
Total Debt (Recent Filing)₹85.00M
Price to Earnings (P/E)21.3
Beta1.32
Next Earnings
May 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.31%
Share Statistics
EPS (TTM)21.80
Shares Outstanding76,011,696
10 Day Avg. Volume2,866
30 Day Avg. Volume3,752
Financial Highlights & Ratios
PEG Ratio1.63
Price to Book (P/B)5.30
Price to Sales (P/S)7.78
P/FCF Ratio62.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)91.6
Revenue Forecast (FY)₹23.73B
Bulls Say, Bears Say
Bulls Say
Revenue & ProfitabilityConsistent multi-year revenue expansion and strong gross/EBITDA/net margins indicate the company can generate sustained operating profits. This durable profitability supports reinvestment in products and markets, funds working capital, and provides resilience to cyclical demand changes over 2–6 months.
Balance Sheet StrengthA conservative leverage profile and a high equity ratio give the company financial flexibility to fund capex or absorb shocks without stressing cash flow. Strong ROE trends show efficient capital use, enabling strategic investments or selective M&A without undermining solvency.
Cash Flow GenerationReliable operating and free cash flow ensures the business can sustain operations, invest in manufacturing capacity, service obligations, and return capital. Robust cash conversion reduces refinancing risk and supports durable capital allocation decisions across cycles.
Bears Say
Regulatory ExposureOperating in diverse regulatory environments increases ongoing compliance and approval risk; inspections or changing local rules can delay market access or restrict sales. This structural exposure can meaningfully affect product availability and revenue visibility over months.
Manufacturing ComplexityFocus on injectables and ophthalmics entails higher technical, quality and capital requirements. Specialized plants face greater inspection and capacity risks; any disruption or need for additional capex to meet standards can constrain supply and pressure margins over the medium term.
Limited Investor GuidanceAbsence of earnings-call disclosures and formal guidance reduces forward visibility for investors and stakeholders. Limited communication can obscure near-term operational trajectories and capital plans, potentially increasing perceived execution risk and affecting strategic decision-making.
Caplin Point Laboratories Limited News
CAPLIPOINT FAQ
What was Caplin Point Laboratories Limited’s price range in the past 12 months?
Caplin Point Laboratories Limited lowest stock price was ₹1502.45 and its highest was ₹2396.95 in the past 12 months.
What is Caplin Point Laboratories Limited’s market cap?
Caplin Point Laboratories Limited’s market cap is ₹131.17B.
When is Caplin Point Laboratories Limited’s upcoming earnings report date?
Caplin Point Laboratories Limited’s upcoming earnings report date is May 14, 2026 which is in 14 days.
How were Caplin Point Laboratories Limited’s earnings last quarter?
Caplin Point Laboratories Limited released its earnings results on Feb 05, 2026. The company reported ₹21.8 earnings per share for the quarter, beating the consensus estimate of N/A by ₹21.8.
Is Caplin Point Laboratories Limited overvalued?
According to Wall Street analysts Caplin Point Laboratories Limited’s price is currently Overvalued.
Does Caplin Point Laboratories Limited pay dividends?
Caplin Point Laboratories Limited pays a Quarterly dividend of ₹3 which represents an annual dividend yield of 0.31%. See more information on Caplin Point Laboratories Limited dividends here
What is Caplin Point Laboratories Limited’s EPS estimate?
Caplin Point Laboratories Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Caplin Point Laboratories Limited have?
Caplin Point Laboratories Limited has 76,011,696 shares outstanding.
What happened to Caplin Point Laboratories Limited’s price movement after its last earnings report?
Caplin Point Laboratories Limited reported an EPS of ₹21.8 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.419%.
Which hedge fund is a major shareholder of Caplin Point Laboratories Limited?
Currently, no hedge funds are holding shares in IN:CAPLIPOINT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Caplin Point Laboratories Limited
Caplin Point Laboratories Limited develops, produces, markets, and exports generic pharmaceutical formulations and branded products in India. The company provides liquid and lyophilized injections, ophthalmic products, tablets, liquid orals, capsules, softgel capsules, suppositories and ovules, powder for injection, dry syrups, topicals, inhalers, IV infusions, lyophilized products, branded products, dermo cosmetics, and other products. It also operates QueTenX, an e-commerce website. The company was incorporated in 1990 and is headquartered in Chennai, India.
Technical Analysis
Alembic Pharmaceuticals Limited
―
―
Granules India Limited
―
NATCO Pharma Limited
―
Neuland Laboratories Ltd.
―